MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5-10% of primitive myelofibrosis (PMF) cases as decisive oncogenic events capable of triggering the disease. Here we report additional mutations located in exon 10 of MPL in PMF patients. We investigated whether these new mutations also lead to cell transformation. MPL exon 10 was systematically sequenced in 100 PMF patients. Seven different mutations were found in eight patients. We introduced each MPL mutant in Ba/F3 cells to determine whether they correspond to gain-of-function mutations. Only MPL W515 mutations induced (1) Ba/F3 proliferation independently of growth factors, (2) tumorigenesis in nude mice, (3) spontaneous activation of JAK/STAT, RAS/MAPK and PI3K transduction pathways and (4) increased S phase of cell cycle. Similar to all other myeloproliferative disorder oncogenic events identified to date, these results demonstrate that only the detected MPL W515 mutations trigger spontaneous MPL activation leading to a G 1 /S transition activation. The other mutations are devoid of significant transforming activity but may synergize with JAK2 V617F or other not yet characterized molecular events.
Introduction
The classical chronic myeloproliferative disorders (MPDs) include chronic myeloid leukemia, polycythemia vera, essential thrombocytemia (ET) and primitive myelofibrosis (PMF). 1 MPDs are hematological diseases characterized by a clonal proliferation of one or several myeloid lineages 2 arising from the transformation of a multipotent hematopoietic stem cell by an oncogenic event such as Bcr-abl fusion protein kinase, mutated Janus kinase JAK2 V617F or thrombopoietin receptor (TPO-R) MPL W515L that induces constitutive signaling. [3] [4] [5] However, approximately 40% of patients with ET and PMF do not present such mutations, [6] [7] [8] [9] [10] [11] and genetic analysis is still under progress to elucidate the responsible oncogenic events.
Recently, MPL W515 mutations have been discovered in 5 and 1% of JAK2 V617F-negative PMF and ET, respectively. The original MPL mutation identified is the substitution of the tryptophan in position 515 by a leucine (MPL W515L) and has been shown to result in the constitutive activation of JAK-STAT signaling and cytokine-independent proliferation of hematopoietic cells. 12 Furthermore, retroviral transduction of MPL W515L into hematopoietic stem cell followed with transplantation in lethally irradiated mice induces a lethal MPD accompanied with thrombocytosis and myelofibrosis. The MPL W515K mutant was later identified by sequencing granulocytes from 1182 MPD patients, 11 but its precise effect on signaling has not been described. W515 is a key amino acid located in the unique amphipathic domain of the MPL receptor that prevents its spontaneous activation. 13 This five amino-acid domain (KWQFP and RWQFP in the mouse and human, respectively) is located in the cytoplasmic juxtamembrane domain of MPL. In the mouse, substitutions of either W508, the equivalent of human W515, for a serine or an alanine or K507 for an alanine have been shown to induce a factor-independent growth of the Ba/F3 cell line. [12] [13] [14] There is evidence that the K and L point mutations in the amphipathic domain of human MPL (position W515) change the spatial conformation of MPL and induce JAK2 autophosphorylation and activation probably by getting in close proximity to JAK2 molecules. In addition, the transmembrane (TM) domain is also crucial in the structure of cytokine receptors and some mutations can promote or facilitate their dimerization. Such a mutation of MPL leading to the substitution of a serine in 505 for an asparagine (MPL S505N) has been described in familial ET. 15 Therefore, it was possible that other amino-acid changes than W515L or W515K either in the amphipathic domain or the TM domains of MPL could be new initiating events in PMF by inducing a constitutive signaling. To test this hypothesis, we sequenced MPL exon 10 in 100 PMF samples; this exon encodes the TM and cytoplasmic juxtamembrane domains of MPL. Once other mutations were identified, we tested their effects on proliferation, cell cycle in in vitro models and on tumor generation in immunodeficient animals. Furthermore, we investigated the mechanisms of activation by MPL point mutations found in PMF patients and attempted to identify targets that would help the development and implementation of directed therapies for the treatment of related disorders.
Materials and methods

Patients and genotyping
The study was approved by the Local Research Ethic Committees of the different hospital center participants. Baseline characteristics and diagnostic information were collected prospectively, and clinical diagnoses were defined according to the Italian criteria for PMF. Erythrocytes were removed by sedimentation with Dextran (Sigma-Aldrich, St Louis, MO, USA). Granulocytes were further fractionated on a Biocoll density gradient centrifugation (1077 g per cm 3 ). Total blood DNA or DNA isolated from granulocytes was purified with a Qiagen kit (Qiagen, Courtabeouf, France). Direct sequencing was performed on DNA corresponding to the different cell fractions. Samples were first subjected to 35 cycles of PCR amplification under the following conditions: denaturing at 94 1C for 30 s, annealing at 58 1C for 2 min, extension at 72 1C for 30 s and a final extension at 72 1C for 5 min. The resulting PCR products were subsequently purified on a Qiagen column and subjected to sequencing on an ABI PRISM 3100 Genetic Analyser (Applied Biosystems, Foster City, CA, USA).
Cell culture
The murine pro-B Ba/F3 cell line was from Immunex Corporation (Seattle, WA, USA). Ba/F3 cells were seeded at a density of 1 Â 10 5 cells per ml and grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Cergy Pontoise, France) containing 10% fetal bovine serum (FBS), antibiotics (100 IU/ml penicillin and 50 mg/ml streptomycin) and 5% WEHI supernatant (a source of interleukin 3 (IL3) from WEHI-3B cell culture medium).
MPL plasmids and stable cell lines
Human MPL WT cDNA (provided by JL Villeval) cloned into Zen-Neo plasmid 16 served as template for site-directed mutagenesis using plaque-forming unit DNA polymerase (Stratagene, La Jolla, CA, USA). With specific primers for the mutations in exon 10 of MPL, we created the different MPL mutants. These plasmids were transfected by electroporation (Nucleofector II, Amaxa, Gaithersburg, MD, USA) in the Ba/F3 cell line. The different cell lines generated were selected during 7 days using 1 mg/ml of Geneticin (Invitrogen Corp., Carlsbad, CA, USA).
Assessment of cell growth
For testing growth factor independency or TPO-dependent growth, cells were washed three times with PBS and cultured in DMEM medium containing 10% FBS without cytokines or with 10 ng/ml TPO (generous gift from Kyrin laboratories, Tokyo, Japan). After 24-72 h, viable cells were counted using the Trypan blue exclusion test.
Apoptosis assays
Annexin V fluorescein isothiocyanate (FITC) (detection of exposed membrane phospholipid phosphatidylserine)-positive staining was determined by fluorescence-activated cell sorting (FACS) analysis according to the manufacturer's recommendations (BD Pharmingen, Franklin Lakes, NJ, USA) in cytokinedeprived cells or cells grown with TPO for 24 h. In similar cell samples, caspase 3 activity was measured using Phiphilux-G 1 D 2 substrate (OncoImmunin Inc., Kensington, MD, USA) 17 following the manufacturer's protocol.
Cell-cycle analysis
Cells were grown in presence of IL3, TPO or without cytokines. After 24 h, 300 000 cells for each condition were incubated overnight in pH 7.6 buffer (1 mg/ml Tris NaCitrate and 0.58 mg/ml NaCl) with 0.1% Igepal (Sigma-Aldrich), 50 mg/ml RNase (Sigma-Aldrich) and 25 mg/ml propidium iodide (Sigma-Aldrich). Cell-cycle parameters were determined by flow cytometric analysis using a FACSsort cytometer (Becton Dickinson, CA, USA). 5-Bromo-2-deoxyuridine (BrdU) labeling was performed using FITC BrdU Flow Kit (BD Biosciences, Le Pont de Claix, France) according to the manufacturer's protocol. Cells were grown for 12 h with IL3, TPO or without cytokines and were labeled during 1 h with BrdU at 37 1C in 5% CO 2 atmosphere.
Immunoblotting
Proteins were extracted in RIPA buffer with 1% Triton X-100 (Sigma-Aldrich) and supplemented with protease inhibitor mixture tablets (Complete, Roche Diagnostics, Meylan, France). Protein (20- 
Assessment of nude mice tumorigenesis
To assess the transforming activity of MPL mutant cells, Ba/F3 cells transfected with MPL WT or the various MPL mutants were subcutaneously transplanted into nude mice (5-to 6-week old). 18 MPL-expressing Ba/F3 cells were seeded at 5 Â 10 7 cells per ml in DMEM medium, and 0.1 ml of suspension was injected into each mouse. There were 10 animals per group. Skin tumor sizes in each group were measured 10 days after injection. Spleens were photographed and weighed 20 days after tumor cells inoculations.
JAK inhibitor assays
For cell-proliferation assays, Ba/F3 cells stably expressing MPL WT, W515L or W515K and K562 were grown in DMEM/10% FBS and then incubated with appropriate concentrations of JAK Inhibitor I (Calbiochem, San Diego, CA, USA) for 18 h. The percentage of S phase was determined by propidium iodide analysis (see cell-cycle analysis). Cell lines incubated in the same conditions were analyzed by western blotting.
Results
Mutations in trans-and juxtamembrane MPL domains
The RWQFP amphipathic domain of the human TPO-R (MPL) forms the hinge between the TM and the cytoplasmic domain of the receptor. Different studies have demonstrated that both the amphipathic and the TM domains of MPL are crucial for signaling. 13, 14, [19] [20] [21] We investigated whether PMF patients have other MPL mutations in these domains. We sequenced MPL exon 10 for 100 PMF patients (Figure 1a) . We detected seven mutations in the amphipathic and TM domains (Figure 1b) . Three of these mutations represent new single nucleotide nonsynonymous substitutions (A506T, G4A1516; L510P, T4C1529 and A519T, G4A1555). Interestingly, the A506T and A519T MPL mutations were associated with the JAK2 V617F mutation in a same patient. The four other mutations had been previously described. MPL S505N was detected in one case of our cohort and had been described in cases of familial ET. 15 Three different mutations of W515: MPL W515L (three patients), MPL W515K (one patient) and MPL W515A (one patient) had been previously found in a subset of ET and PMF [11] [12] [13] (Figure 1c) .
Effects of the different MPL mutations on proliferation and apoptosis
The MPL S505N and W515A mutants have previously been characterized. 13, 15, 19 To accurately compare the effects of the other mutations on the constitutive activation of MPL, directed-site mutagenesis was performed using an expression vector for MPL as template. Concerning the two MPL mutations detected in one single patient (harboring also a JAK2 V617F mutation), we decided to study each MPL mutant individually. In addition, we constructed a vector carrying simultaneously the G4A1516 and G4A1555 mutations as we had indirect evidence that these two substitutions could be located on the same copy of MPL. Expression vectors for the different MPL mutants were transfected in Ba/F3 and stable cell lines were generated by geneticin selection for 7 days. We verified that the different MPL mutants presented similar expression both at the RNA (data not shown) and at the protein (Figure 2a ) levels in the Ba/F3 cell lines. Cell lines were cultured in DMEM/10% FBS with IL3, TPO (10 ng/ml) or without cytokine, accordingly. Indeed, autonomous growth of Ba/F3 cells is commonly used as a readout for transforming activity as Ba/F3 cells are entirely dependent upon cytokines for normal growth. 22 To ensure that all these mutants were functional, we tested the TPO-dependent proliferation at day 7. As shown in Figure 2b all cell lines grew 
Effects of the different MPL mutants on signal transduction
We then assessed the effects of MPL mutants on spontaneous phosphorylation of different signal transduction pathways. 23 Cells were deprived of cytokines during 12 h in DMEM 1% FBS. Only MPL W515L and W515K induced a spontaneous phosphorylation of Jak2, Stat5, Stat3, Akt and p44/42 MAPK (Figure 3a) . Notably, the phosphorylation levels of these different signaling proteins were higher in TPO-stimulated compare to cytokine-deprived cells (data not shown). We observed the associated expression of the antiapoptotic Bcl-xL protein 24 h after cytokine withdrawal (Figure 3b) . (Figures 4a and  b) . Similarly, metastases were only observed with MPL W515L or K Ba/F3 cells (Figures 4c and d) .
MPL W515 promotes the Ba/F3 to enter the cell cycle and spontaneously activates the G 1 /S cell-cycle phase transition
To determine at which step of the cell cycle the MPL W515 mutations confer an advantage to proliferate, BrdU-incorporation assays were performed. Consistent with the proliferation assays (Figure 5a ), BrdU-incorporation assays showed that after 12 h of culture in cytokine-deficient medium, only Ba/F3 cells harboring MPL W515 mutations were being driven into S phase and were actively synthesizing DNA. Indeed, 26% Ba/F3 MPL W515L cells and 30% Ba/F3 MPL W515K cells were in S phase, whereas 13 and 7% were in S phase for the 2 Ba/F3 control cell lines (Ba/F3 MPL WT or parental Ba/F3). However, this S-phase entry was not maximal as 50-70% of cells advanced in S phase following either TPO or IL3 stimulation, irrespectively of the presence of MPL W515 mutants (Figure 5b ). To clearly identify how MPL W515 mutants regulate cell-cycle entry, we studied expression of the transcription factor E2F1 and its cell-cycle activity through Rb phosphorylation. E2F1 expression and Rb phosphorylation also were detected in cytokine-deprived Ba/F3-expressing MPL W515 mutations but not in the other Ba/F3 cell lines. Baseline level was increased by TPO or IL3 in all Ba/F3 cell lines. Moreover, proteins associated with late G 1 , early and late S phases such as cyclins D1 and D3, PCNA, cyclins E and A were detected (Figure 6a ), confirming that Ba/F3 W515 cells were cycling without cytokine addition. These results were in agreement with the propidium iodide staining (Figure 6b ) and the BrdU-incorporation assays (Figure 5b ). All these findings are consistent with a spontaneous cell growth induced by MPL W515 mutations by promotion of G 1 /S-phase transition.
MPL W515 mutation effects can be inhibited by JAK inhibitor I
We tested whether MPL W515 mutation-induced spontaneous S-phase entry was a direct consequence of JAK activation by MPL and whether PMF harboring MPL W515 mutations could be treated with JAK inhibitors 24 such as the JAK2 V617F PMF patients. We investigated the effects of JAK inhibition in Ba/F3 cells (1) on cell-cycle progression and more precisely on the ratio of cells in S phase despite cytokine withdrawal and (2) on Rb phosphorylation and PCNA expression. Ba/F3 cells transfected with JAK2 V617F were concomitantly used to determine a possible change in the sensitivity of the different MPL mutants to the inhibitor. K562 cells harbor a Bcr-abl translocation responsible for their JAK2-independent spontaneous growth and were used as a negative control. 25, 26 MPL W515 mutated Ba/F3 cells had similar sensitivities to JAK inhibitor I than JAK2 V617F Ba/F3 cells. As expected, even high doses of the JAK inhibitor I had no effect on cell-cycle progression of K562 (Figures 7a and b) .
Discussion
The molecular mechanisms of the majority of JAK2-negative MPDs are unknown but the recent discovery of activating mutations in the TPO-R MPL has opened new avenues of investigations. All the mutations presently detected in rare PMF and ET involved a change in the tryptophan 515 located in the amphipathic domain of MPL. This domain is composed of five amino acids (KWQFP in the mouse and RWQFP in human), located at the junction of the TM and the cytoplasmic domains and is important in maintaining the MPL receptor inactive in the absence of TPO. In the murine KWQFP motif, it has been shown that the substitution of K or W for A induced a spontaneous activation of the receptor. 13 In human, the homologous amino acids are the R in 514 and W in 515, and thus may block spontaneous receptor activation. There is evidence that growth factor independency conferred by the different oncogenic forms of MPL is related to a spontaneous homodimerization of the receptor. The viral oncogenic form of MPL, v-MPL, is characterized by the deletion of its extracellular domain. 21 Its homodimerization results from the fusion of the truncated MPL sequence with the virus envelope. Furthermore, introduction of a cysteine residue at codon 368 leads to a covalent disulfidebonded homodimerization and ligand-independent receptor activation. 20 Similarly, the forced dimerization of MPL, using monoclonal antibodies or the FK506-binding protein FKPB12 induces a factor-independent proliferation. 27 In JAK2-negative MPDs, MPL W515L mutation has initially been identified in PMF cases. MPL W515L is capable of inducing independence in growth factors and also a lethal MPD in the mouse, similarly as the Delta5 MPL (devoid of the amphipathic domain) or the W515A mutant (S Constantinescu, personal communication). This clearly demonstrates that W515L mutant is really an oncogenic form of MPL. This spontaneous activation of the receptor seems to be related to changes in the helicoidal structure and the loss of interaction of the 515 residue with the membrane, allowing a spontaneous activation of JAK2. 13 Knowing the importance of the region spanning on each side of the amphipathic motif including the TM domain, we sequenced the exon 10 of MPL in 100 PMF patients to search for new mutations.
Seven different mutations were found in the exon 10 which were not identified in the public single nucleotide polymorphism database according to the ethnic origin of patients. We could not investigate whether these mutations were acquired or germline because sequencing was performed on sample banking. New samples permitting to separate tumoral from nontumoral cells were not available as in most cases the PMF had a lethal evolution.
Three mutations concerned the W515 residue that was substituted either for a leucine W515L, a lysine W515K or an asparagine W515A. This last natural mutation which was predicted by a mutational approach 13 is found for the first time in patient sample. Strikingly, no mutation in R514 was detected whereas a mutational approach in the mouse has suggested that it was a key residue to prevent MPL activation. Four other mutations were found outside the amphipathic domain and included the S505N mutant that has been previously identified in a familial form of thrombocytosis in childhood. 15 This mutation has been associated with an autosomic dominant transmission but in our case seems to be acquired as no other cases of thrombocytosis nor PMF were present in the family. This is the first time that this mutation is identified in a sporadic MPD, suggesting promiscuity between the molecular mechanisms of inherited thrombocytosis and erythrocytosis and sporadic MPD. All three other mutations (A506T, L510P and A519T) have not been previously described. The A506T and A519T mutations were found in the same patient, in association with JAK2 V617F.
Therefore, we studied whether these new mutants had acquired a gain-of-function using the Ba/F3 cell line and if they were directly implicated in the pathogenesis of the disease. In fact none of these mutants nor double mutants (A506T, A519T) could induce spontaneous cell growth, tumorigenesis or spontaneous activation of the main receptor transduction pathways using the Ba/F3 assay, indicating that these mutations are not oncogenic by themselves. Controversial results have been reported with the S505N mutant previously found in a familial form of childhood thrombocytosis. 15 Indeed, the human S505N mutant transfected in Ba/F3 only induced a transient survival without proliferation whereas the same mutation on the murine receptor (S498N) abrogated factor dependence of the Ba/F3 cell line and rendered them tumorigenic in syngeneic mice. 19 These differences could be related to the use of receptors from two different species but it is more likely due to the level of expression of the receptor. Indeed, in the second study a retroviral vector was used to obtain a Ba/F3 MPL cell line.
The W515K mutant had never been functionally characterized and behaves as W515L, inducing survival, proliferation and tumorigenesis. Previous works on myeloproliferative genetic events have demonstrated that fusion tyrosine kinases such as Bcr-abl 28 or Tel-JAK2, 29, 30 and JAK2 V617F 31 induce both survival and a spontaneous G 1 /S transition that might be mediated by Stat5 and Pi3 kinase activation. Therefore, these activated kinases mimic effects of growth factors. MPL W515L and W515K promoted G 1 /S transition after cytokine withdrawal. This was confirmed by the expression of cell-cycle regulators cyclins D1, A, E and D3, and also spontaneous phosphorylation on Ser608 and 780 of Rb leading to expression of E2F and PCNA. These oncogenic forms of MPL by constitutively activating JAK2 have the same behavior as gain-of-function mutation of JAK2 such as JAK2 V617F. Indeed, it has previously been shown, and we confirmed this result, that a JAK inhibitor I blocks the effects of W515L. This explains the similar effects on megakaryocyte proliferation observed in presence of JAK2 V617F with wild-type MPL and of MPL W515 mutations.
The significance of the three (A506T, L510P and A519T) other mutants in the pathogenesis of the disease remains to be clarified. There are two main hypothesis independently of the acquired or germ line status of these mutants. First, they may have no relevance to the disease and second, they may be regulators of other genetic events. Strikingly the double A506T and A519T mutation was found in a JAK2 V617F PMF and may have induced phenotypic changes. These mutants could be not previously described rare polymorphisms or acquired mutations, which might be related to JAK2 V617F-induced gene instability (I Plo, unpublished observations). Interestingly, no linkage disequilibrium in known single nucleotide polymorphism loci of MPL in PMF has been described to date. Recently Williams et al.
32
, have found a new MPL mutant (S204P) outside the exon 10 and intervening sequence of the splice recognition sites of exons 10 and 11. However, in this study whether theses mutants were gain-of-function mutants or acquired was not determined. Malinge et al. have also described a new gain-of-function MPL mutant (T487A) in acute megakaryoblastic leukemia with similar properties than MPL W515 mutants (S Malinge, unpublished observations). Further studies will be required to determine the exact frequency of these mutants and their precise role in the pathogenesis of PMF.
Altogether this study shows that a mutant of MPL (S505N) implicated in familial thrombocytosis is also associated with sporadic MPD and that other rare MPL W515 mutants are associated with MPDs as possible regulators of JAK2 V617F or other unknown genetic events. 
